<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240328141103&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240328141103&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 28 Mar 2024 18:11:04 +0000</lastbuilddate>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Blood stream infection in defibrillator recipients: cardiac imaging for all patients or sometimes skillful neglect?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38546417/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 28:ehae025. doi: 10.1093/eurheartj/ehae025. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38546417/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38546417</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae025>10.1093/eurheartj/ehae025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38546417</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Maria Grazia Bongiorni</dc:creator>
<dc:creator>Giulio Zucchelli</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Blood stream infection in defibrillator recipients: cardiac imaging for all patients or sometimes skillful neglect?</dc:title>
<dc:identifier>pmid:38546417</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae025</dc:identifier>
</item>
<item>
<title>Cardiac implantable electronic devices and bloodstream infections: management and outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38546408/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Diagnostic workup of defibrillator patients with BSI admitted to a non-cardiology unit is often insufficient to characterize lead-related endocarditis. The high mortality rate in these patients with BSI may relate to underdiagnosis and consequently late/absence of system removal. Efforts to increase an interdisciplinary approach and greater use of cardiac imaging are necessary for timely diagnosis and adequate treatment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 28:ehae127. doi: 10.1093/eurheartj/ehae127. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Bloodstream infection (BSI) of any cause may lead to device infection in cardiac implantable electronic device (CIED) patients. Aiming for a better understanding of the diagnostic approach, treatment, and outcome, patients with an implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy and defibrillator (CRT-D) hospitalized with BSI were investigated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This is a single-centre, retrospective, cohort analysis including consecutive ICD/CRT-D patients implanted between 2012 and 2021. These patients were screened against a list of all hospitalized patients having positive blood cultures consistent with diagnosed infection in any department of a local public hospital.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The total cohort consisted of 515 patients. Over a median follow-up of 59 months (interquartile range 31-87 months), there were 47 BSI episodes in 36 patients. The majority of patients with BSI (92%) was admitted to non-cardiology units, and in 25 episodes (53%), no cardiac imaging was performed. Nearly all patients (85%) were treated with short-term antibiotics, whereas chronic antibiotic suppression therapy (n = 4) and system extraction (n = 3) were less frequent. Patients with BSI had a nearly seven-fold higher rate (hazard ratio 6.7, 95% confidence interval 3.9-11.2; P &lt; .001) of all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Diagnostic workup of defibrillator patients with BSI admitted to a non-cardiology unit is often insufficient to characterize lead-related endocarditis. The high mortality rate in these patients with BSI may relate to underdiagnosis and consequently late/absence of system removal. Efforts to increase an interdisciplinary approach and greater use of cardiac imaging are necessary for timely diagnosis and adequate treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38546408/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38546408</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae127>10.1093/eurheartj/ehae127</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38546408</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Tardu Özkartal</dc:creator>
<dc:creator>Andrea Demarchi</dc:creator>
<dc:creator>Giulio Conte</dc:creator>
<dc:creator>Damiano Pongan</dc:creator>
<dc:creator>Catherine Klersy</dc:creator>
<dc:creator>Maria Luce Caputo</dc:creator>
<dc:creator>Marco Bergonti</dc:creator>
<dc:creator>Enos Bernasconi</dc:creator>
<dc:creator>Valeria Gaia</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Angelo Auricchio</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiac implantable electronic devices and bloodstream infections: management and outcomes</dc:title>
<dc:identifier>pmid:38546408</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae127</dc:identifier>
</item>
<item>
<title>Advancing Wearable Biosensors for Congenital Heart Disease: Patient and Clinician Perspectives: A Science Advisory From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38545775/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>Wearable biosensors (wearables) enable continual, noninvasive physiologic and behavioral monitoring at home for those with pediatric or congenital heart disease. Wearables allow patients to access their personal data and monitor their health. Despite substantial technologic advances in recent years, issues with hardware design, data analysis, and integration into the clinical workflow prevent wearables from reaching their potential in high-risk congenital heart disease populations. This science...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 28. doi: 10.1161/CIR.0000000000001225. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Wearable biosensors (wearables) enable continual, noninvasive physiologic and behavioral monitoring at home for those with pediatric or congenital heart disease. Wearables allow patients to access their personal data and monitor their health. Despite substantial technologic advances in recent years, issues with hardware design, data analysis, and integration into the clinical workflow prevent wearables from reaching their potential in high-risk congenital heart disease populations. This science advisory reviews the use of wearables in patients with congenital heart disease, how to improve these technologies for clinicians and patients, and ethical and regulatory considerations. Challenges related to the use of wearables are common to every clinical setting, but specific topics for consideration in congenital heart disease are highlighted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38545775/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38545775</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001225>10.1161/CIR.0000000000001225</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38545775</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Animesh Tandon</dc:creator>
<dc:creator>Jennifer N Avari Silva</dc:creator>
<dc:creator>Ami B Bhatt</dc:creator>
<dc:creator>Colin K Drummond</dc:creator>
<dc:creator>Allison C Hill</dc:creator>
<dc:creator>Amanda E Paluch</dc:creator>
<dc:creator>Sheradon Waits</dc:creator>
<dc:creator>Jenny E Zablah</dc:creator>
<dc:creator>Kevin C Harris</dc:creator>
<dc:creator>Council on Lifelong Congenital Heart Disease and Heart Health in the Young (Young Hearts); Council on Lifestyle and Cardiometabolic Health; Council on Clinical Cardiology; and Council on Cardiovascular and Stroke Nursing</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Advancing Wearable Biosensors for Congenital Heart Disease: Patient and Clinician Perspectives: A Science Advisory From the American Heart Association</dc:title>
<dc:identifier>pmid:38545775</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001225</dc:identifier>
</item>
<item>
<title>Artificial intelligence-based assessment of built environment from Google Street View and coronary artery disease prevalence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38544295/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this cross-sectional study, the prevalence of CHD was associated with built environment factors derived from GSV through deep learning analysis, independent of census tract demographics. Machine vision-enabled assessment of the built environment could potentially offer a more precise approach to identify at-risk neighbourhoods, thereby providing an efficient avenue to address and reduce cardiovascular health disparities in urban environments.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 28:ehae158. doi: 10.1093/eurheartj/ehae158. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Built environment plays an important role in the development of cardiovascular disease. Tools to evaluate the built environment using machine vision and informatic approaches have been limited. This study aimed to investigate the association between machine vision-based built environment and prevalence of cardiometabolic disease in US cities.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This cross-sectional study used features extracted from Google Street View (GSV) images to measure the built environment and link them with prevalence of coronary heart disease (CHD). Convolutional neural networks, linear mixed-effects models, and activation maps were utilized to predict health outcomes and identify feature associations with CHD at the census tract level. The study obtained 0.53 million GSV images covering 789 census tracts in seven US cities (Cleveland, OH; Fremont, CA; Kansas City, MO; Detroit, MI; Bellevue, WA; Brownsville, TX; and Denver, CO).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Built environment features extracted from GSV using deep learning predicted 63% of the census tract variation in CHD prevalence. The addition of GSV features improved a model that only included census tract-level age, sex, race, income, and education or composite indices of social determinant of health. Activation maps from the features revealed a set of neighbourhood features represented by buildings and roads associated with CHD prevalence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this cross-sectional study, the prevalence of CHD was associated with built environment factors derived from GSV through deep learning analysis, independent of census tract demographics. Machine vision-enabled assessment of the built environment could potentially offer a more precise approach to identify at-risk neighbourhoods, thereby providing an efficient avenue to address and reduce cardiovascular health disparities in urban environments.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38544295/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38544295</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae158>10.1093/eurheartj/ehae158</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38544295</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Zhuo Chen</dc:creator>
<dc:creator>Jean-Eudes Dazard</dc:creator>
<dc:creator>Yassin Khalifa</dc:creator>
<dc:creator>Issam Motairek</dc:creator>
<dc:creator>Sadeer Al-Kindi</dc:creator>
<dc:creator>Sanjay Rajagopalan</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence-based assessment of built environment from Google Street View and coronary artery disease prevalence</dc:title>
<dc:identifier>pmid:38544295</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae158</dc:identifier>
</item>
<item>
<title>Artificial intelligence-enhanced exposomics: novel insights into cardiovascular health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38544282/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 28:ehae159. doi: 10.1093/eurheartj/ehae159. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38544282/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38544282</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae159>10.1093/eurheartj/ehae159</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38544282</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Rohan Khera</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence-enhanced exposomics: novel insights into cardiovascular health</dc:title>
<dc:identifier>pmid:38544282</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae159</dc:identifier>
</item>
<item>
<title>Reply: Evaluation of the Inclisiran Safety in High-Risk Populations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538207/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):e129. doi: 10.1016/j.jacc.2024.01.032. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538207/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38538207</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.032>10.1016/j.jacc.2024.01.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538207</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>R Scott Wright</dc:creator>
<dc:creator>Lawrence A Leiter</dc:creator>
<dc:creator>Anastasia Lesogor</dc:creator>
<dc:creator>Kausik K Ray</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Evaluation of the Inclisiran Safety in High-Risk Populations</dc:title>
<dc:identifier>pmid:38538207</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.032</dc:identifier>
</item>
<item>
<title>Evaluation of the Inclisiran Safety in High-Risk Populations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538206/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):e127. doi: 10.1016/j.jacc.2023.12.037. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538206/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38538206</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.037>10.1016/j.jacc.2023.12.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538206</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Xin Jiang</dc:creator>
<dc:creator>Zhengjun Zhang</dc:creator>
<dc:creator>Hao Ding</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Evaluation of the Inclisiran Safety in High-Risk Populations</dc:title>
<dc:identifier>pmid:38538206</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.037</dc:identifier>
</item>
<item>
<title>Mitral Transcatheter Edge-to-Edge Repair in Patients With Atrial Functional Mitral Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538205/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):1253-1255. doi: 10.1016/j.jacc.2024.01.031. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538205/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38538205</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.031>10.1016/j.jacc.2024.01.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538205</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Errol Moras</dc:creator>
<dc:creator>Kruti Gandhi</dc:creator>
<dc:creator>Anoop N Koshy</dc:creator>
<dc:creator>Kirtipal Bhatia</dc:creator>
<dc:creator>Chayakrit Krittanawong</dc:creator>
<dc:creator>Abel Casso Dominguez</dc:creator>
<dc:creator>Edgar Argulian</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Mitral Transcatheter Edge-to-Edge Repair in Patients With Atrial Functional Mitral Regurgitation</dc:title>
<dc:identifier>pmid:38538205</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.031</dc:identifier>
</item>
<item>
<title>Enhanced Decongestive Therapy in Patients With Acute Heart Failure: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538204/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>Because signs of congestion are associated with adverse outcomes in patients with acute heart failure (AHF), attempts were made to decongest patients as much as possible with diuretic agents (loop diuretic agents, thiazides, acetazolamide) or mechanical devices. Those interventions improved signs of congestion but failed to meaningfully improve patients' symptoms, improve quality of life, or reduce early readmissions or deaths. Recent studies have shown that implementation of guideline-directed...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):1243-1252. doi: 10.1016/j.jacc.2024.01.029. Epub 2024 Mar 25.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Because signs of congestion are associated with adverse outcomes in patients with acute heart failure (AHF), attempts were made to decongest patients as much as possible with diuretic agents (loop diuretic agents, thiazides, acetazolamide) or mechanical devices. Those interventions improved signs of congestion but failed to meaningfully improve patients' symptoms, improve quality of life, or reduce early readmissions or deaths. Recent studies have shown that implementation of guideline-directed medical therapies after an AHF admission led to both more decongestion and improved symptoms, quality of life, and outcomes. Therefore, for most patients with AHF whose symptoms and congestion can be controlled with loop diuretic agents, the main focus should be rapid guideline-directed medical therapy uptitration. Enhanced decongestion, ie, adding a second-line diuretic agent to a loop diuretic agent, should be reserved for those patients who do not respond to loop diuretic agents.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538204/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38538204</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.029>10.1016/j.jacc.2024.01.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538204</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Gad Cotter</dc:creator>
<dc:creator>Beth Davison</dc:creator>
<dc:creator>Ovidiu Chioncel</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Enhanced Decongestive Therapy in Patients With Acute Heart Failure: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:38538204</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.029</dc:identifier>
</item>
<item>
<title>Need for 'One-Stop-Shop' Heart-Brain-Placental Imaging in Fetal Congenital Heart Disease: Fetal Hemodynamics Portend Neurodevelopmental Outcome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538203/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):1240-1242. doi: 10.1016/j.jacc.2024.02.022. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538203/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38538203</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.022>10.1016/j.jacc.2024.02.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538203</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Ashok Panigrahy</dc:creator>
<dc:creator>Jodie K Votava-Smith</dc:creator>
<dc:creator>Daniel J Licht</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Need for 'One-Stop-Shop' Heart-Brain-Placental Imaging in Fetal Congenital Heart Disease: Fetal Hemodynamics Portend Neurodevelopmental Outcome</dc:title>
<dc:identifier>pmid:38538203</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.022</dc:identifier>
</item>
<item>
<title>Fetal Hemodynamics, Early Survival, and Neurodevelopment in Patients With Cyanotic Congenital Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538202/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among fetuses with cyanotic CHD, diminished fetal combined ventricular output is associated with mortality, whereas cerebral blood flow and oxygen delivery are associated with early cognitive, language, and motor development at 18 months of age. These results support the inclusion of fetal CMR to help identify patients at risk of adverse ND outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):1225-1239. doi: 10.1016/j.jacc.2024.02.005. Epub 2024 Mar 25.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Fetuses with cyanotic congenital heart disease (CHD) exhibit profound fetal circulatory disturbances that may affect early outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to investigate the relationship between fetal hemodynamics and early survival and neurodevelopmental (ND) outcomes in patients with cyanotic CHD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this longitudinal observational study, fetuses with cyanotic CHD underwent late gestational fetal cardiovascular magnetic resonance (CMR) to measure vessel blood flow and oxygen content. Superior vena cava (SVC) flow was used as a proxy for cerebral blood flow. Primary outcomes were 18-month mortality and Bayley Scales of Infant Development-III assessment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 144 fetuses with cyanotic CHD were assessed. By 18 months, 18 patients (12.5%) died. Early mortality was associated with reduced combined ventricular output (P = 0.01), descending aortic flow (P = 0.04), and umbilical vein flow (P = 0.03). Of the surviving patients, 71 had ND outcomes assessed. Cerebral oxygen delivery was the fetal hemodynamic variable most strongly associated with cognitive, language, and motor outcomes (P &lt; 0.05). Fetal SVC flow was also associated with cognitive, language, and motor outcomes (P &lt; 0.01), and it remained an independent predictor of cognitive (P = 0.002) and language (P = 0.04) outcomes after adjusting for diagnosis. Diminished SVC flow also performed better than other fetal CMR and echocardiographic predictors of cognitive ND delay (receiver-operating characteristic curve area: 0.85; SE 0.05).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among fetuses with cyanotic CHD, diminished fetal combined ventricular output is associated with mortality, whereas cerebral blood flow and oxygen delivery are associated with early cognitive, language, and motor development at 18 months of age. These results support the inclusion of fetal CMR to help identify patients at risk of adverse ND outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538202/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38538202</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.005>10.1016/j.jacc.2024.02.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538202</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Fu-Tsuen Lee</dc:creator>
<dc:creator>Liqun Sun</dc:creator>
<dc:creator>Joshua F P van Amerom</dc:creator>
<dc:creator>Sharon Portnoy</dc:creator>
<dc:creator>Davide Marini</dc:creator>
<dc:creator>Amandeep Saini</dc:creator>
<dc:creator>Natasha Milligan</dc:creator>
<dc:creator>Jessie Mei Lim</dc:creator>
<dc:creator>Brahmdeep Saini</dc:creator>
<dc:creator>Thiviya Selvanathan</dc:creator>
<dc:creator>Vanna Kazazian</dc:creator>
<dc:creator>Renee Sananes</dc:creator>
<dc:creator>Edgar Jaeggi</dc:creator>
<dc:creator>John C Kingdom</dc:creator>
<dc:creator>Christopher K Macgowan</dc:creator>
<dc:creator>Linh Ly</dc:creator>
<dc:creator>Vann Chau</dc:creator>
<dc:creator>Steven P Miller</dc:creator>
<dc:creator>Mike Seed</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Fetal Hemodynamics, Early Survival, and Neurodevelopment in Patients With Cyanotic Congenital Heart Disease</dc:title>
<dc:identifier>pmid:38538202</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.005</dc:identifier>
</item>
<item>
<title>Paclitaxel-Mortality Risk Hypothesis Debunked: What We Learned and How It Will Change Future Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538201/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):1222-1224. doi: 10.1016/j.jacc.2024.02.023. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538201/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38538201</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.023>10.1016/j.jacc.2024.02.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538201</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter A Schneider</dc:creator>
<dc:creator>Jeffrey W Olin</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Paclitaxel-Mortality Risk Hypothesis Debunked: What We Learned and How It Will Change Future Clinical Trials</dc:title>
<dc:identifier>pmid:38538201</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.023</dc:identifier>
</item>
<item>
<title>Mortality in a Nationwide Practice-Based Cohort Receiving Paclitaxel-Coated Devices for Lower Limb Peripheral Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538200/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In a nationwide analysis based on large-scale real-world data, exposure to PCDs was not associated with a higher risk of mortality in patients undergoing endovascular revascularization for lower limb peripheral artery disease. (The DETECT Project; NCT05254106).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):1207-1221. doi: 10.1016/j.jacc.2024.02.003. Epub 2024 Mar 25.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: According to a meta-analysis of randomized clinical trials, paclitaxel-coated devices (PCDs) for lower limb endovascular revascularization may be associated with increased risk of late mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to determine whether PCDs are associated with all-cause mortality in a real-world setting.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: DETECT is a nationwide, exhaustive retrospective cohort study using medico-administrative data from the French National Healthcare System representing >;99% of the population. The main selection criterion was the first procedure of interest: endovascular revascularization for lower limb peripheral artery disease involving ≥1 balloon and/or stent performed between October 1, 2011, and December 31, 2019. Patients with or without PCDs were compared for all-cause mortality until December 31, 2021.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 259,137 patients were analyzed, with 20,083 (7.7%) treated with ≥1 PCD. After a median follow-up of 4.1 years (Q1-Q3: 2.3-6.4 years), a total of 5,385 deaths/73,923 person-years (PY) (7.3/100 PY) and 109,844 deaths/1,060,513 PY (10.4/100 PY) were observed in the PCD and control groups, respectively. After adjustment for confounding factors, PCD treatment was associated with a lower risk of mortality in multivariable Cox analyses (HR: 0.86; 95% CI: 0.84-0.89; P &lt; 0.001). Similar results were observed using propensity score matching approaches based on either nearest-neighbor or exact matching.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In a nationwide analysis based on large-scale real-world data, exposure to PCDs was not associated with a higher risk of mortality in patients undergoing endovascular revascularization for lower limb peripheral artery disease. (The DETECT Project; NCT05254106).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538200/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38538200</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.003>10.1016/j.jacc.2024.02.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538200</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthieu Wargny</dc:creator>
<dc:creator>Christophe Leux</dc:creator>
<dc:creator>Gilles Chatellier</dc:creator>
<dc:creator>Sandrine Coudol</dc:creator>
<dc:creator>Pierre-Antoine Gourraud</dc:creator>
<dc:creator>Yann Gouëffic</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Mortality in a Nationwide Practice-Based Cohort Receiving Paclitaxel-Coated Devices for Lower Limb Peripheral Artery Disease</dc:title>
<dc:identifier>pmid:38538200</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.003</dc:identifier>
</item>
<item>
<title>Rethinking Blood Pressure Treatment and Dementia Risk in Older Adults: Is Adherence the Holy Grail?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538199/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):1204-1206. doi: 10.1016/j.jacc.2024.02.021. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538199/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38538199</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.021>10.1016/j.jacc.2024.02.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538199</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Clinton B Wright</dc:creator>
<dc:creator>Marco Egle</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Rethinking Blood Pressure Treatment and Dementia Risk in Older Adults: Is Adherence the Holy Grail?</dc:title>
<dc:identifier>pmid:38538199</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.021</dc:identifier>
</item>
<item>
<title>Risk of Dementia During Antihypertensive Drug Therapy in the Elderly</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538198/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In the old fraction of the general population, antihypertensive drug treatment is associated with a lower risk of dementia. This was also the case in very old and frail patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):1194-1203. doi: 10.1016/j.jacc.2024.01.030. Epub 2024 Mar 25.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Evidence exists that lowering high blood pressure reduces the risk of dementia. However, the generalizability of this evidence to old patients from the general population remains uncertain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to evaluate the effect of antihypertensive drug treatment on the risk of dementia in a heterogeneous group of new users of antihypertensive drugs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A nested case-control study was carried out by including the cohort of 215,547 patients from Lombardy, Italy, aged ≥65 years, who started taking antihypertensive drugs between 2009 and 2012. Cases were the 13,812 patients (age 77.5 ± 6.6 years; 40% men) who developed dementia or Alzheimer's disease during follow-up (up to 2019). For each case, 5 control subjects were selected to be matched for sex, age, and clinical status. Exposure to drug therapy was measured by the proportion of the follow-up covered by antihypertensive drugs. Conditional logistic regression was used to model the outcome risk associated with exposure to antihypertensive drugs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Exposure to treatment was inversely associated with the risk of dementia. Compared with patients with very low exposure, those with low, intermediate, and high exposure exhibited a 2% (95% CI: -4% to 7%), 12% (95% CI: 6%-17%), and 24% (95% CI: 19%-28%) risk reduction, respectively. This was also the case for very old (aged ≥85 years) and frail patients (ie, those characterized by a high mortality risk at 1 year).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In the old fraction of the general population, antihypertensive drug treatment is associated with a lower risk of dementia. This was also the case in very old and frail patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538198/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38538198</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.030>10.1016/j.jacc.2024.01.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538198</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Federico Rea</dc:creator>
<dc:creator>Giovanni Corrao</dc:creator>
<dc:creator>Giuseppe Mancia</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Risk of Dementia During Antihypertensive Drug Therapy in the Elderly</dc:title>
<dc:identifier>pmid:38538198</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.030</dc:identifier>
</item>
<item>
<title>Chest Pain in the Emergency Department: Chasing Perfection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538197/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):1191-1193. doi: 10.1016/j.jacc.2024.02.018. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538197/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38538197</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.018>10.1016/j.jacc.2024.02.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538197</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael C Kontos</dc:creator>
<dc:creator>James A de Lemos</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Chest Pain in the Emergency Department: Chasing Perfection</dc:title>
<dc:identifier>pmid:38538197</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.018</dc:identifier>
</item>
<item>
<title>Validation of the ACC Expert Consensus Decision Pathway for Patients With Chest Pain</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538196/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The ACC expert consensus decision pathway was safe and efficacious. However, it may not be safe for use among patients with known CAD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):1181-1190. doi: 10.1016/j.jacc.2024.02.004. Epub 2024 Mar 25.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The American College of Cardiology (ACC) recently published an Expert Consensus Decision Pathway for chest pain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to validate the ACC Pathway in a multisite U.S.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: An observational cohort study of adults with possible acute coronary syndrome was conducted. Patients were accrued from 5 U.S. Emergency Departments (November 1, 2020, to July 31, 2022). ECGs and 0- and 2-hour high-sensitivity troponin (Beckman Coulter) measures were used to stratify patients according to the ACC Pathway. The primary safety outcome was 30-day all-cause death or myocardial infarction (MI). Efficacy was defined as the proportion stratified to the rule-out zone. Negative predictive value for 30-day death or MI was assessed among the whole cohort and in a subgroup of patients with coronary artery disease (CAD) (prior MI, revascularization, or ≥70% coronary stenosis).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: ACC Pathway assessments were complete in 14,395 patients, of whom 51.7% (7,437 of 14,395) were women with a median age of 56 years (Q1-Q3: 44-68 years). Known CAD was present in 23.5% (3,386 of 14,395) and 30-day death or MI occurred in 8.1% (1,168 of 14,395). The ACC Pathway had an efficacy of 48.1% (95% CI: 47.3%-49.0%). Among patients in the rule-out zone, 0.3% (22 of 6,930) had death or MI at 30 days, yielding a negative predictive value of 99.7% (95% CI: 99.5%-99.8%). In patients with known CAD, 20.0% (676 of 3,386) were classified to the rule-out zone, of whom 1.5% (10 of 676) had death or MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The ACC expert consensus decision pathway was safe and efficacious. However, it may not be safe for use among patients with known CAD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538196/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38538196</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.004>10.1016/j.jacc.2024.02.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538196</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Simon A Mahler</dc:creator>
<dc:creator>Nicklaus P Ashburn</dc:creator>
<dc:creator>Michael W Supples</dc:creator>
<dc:creator>Tara Hashemian</dc:creator>
<dc:creator>Anna C Snavely</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Validation of the ACC Expert Consensus Decision Pathway for Patients With Chest Pain</dc:title>
<dc:identifier>pmid:38538196</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.004</dc:identifier>
</item>
<item>
<title>Focus on residual cardiovascular risk: air pollution, infections, socioeconomic status, and lipopoprotein(a)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538150/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 27;45(12):971-975. doi: 10.1093/eurheartj/ehae160.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538150/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38538150</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae160>10.1093/eurheartj/ehae160</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538150</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Focus on residual cardiovascular risk: air pollution, infections, socioeconomic status, and lipopoprotein(a)</dc:title>
<dc:identifier>pmid:38538150</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae160</dc:identifier>
</item>
<item>
<title>Severe mental illness: cardiovascular risk assessment and management</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538149/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>Patients with severe mental illness (SMI) including schizophrenia and bipolar disorder die on average 15-20 years earlier than the general population often due to sudden death that, in most cases, is caused by cardiovascular disease. This state-of-the-art review aims to address the complex association between SMI and cardiovascular risk, explore disparities in cardiovascular care pathways, describe how to adequately predict cardiovascular outcomes, and propose targeted interventions to improve...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 27;45(12):987-997. doi: 10.1093/eurheartj/ehae054.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Patients with severe mental illness (SMI) including schizophrenia and bipolar disorder die on average 15-20 years earlier than the general population often due to sudden death that, in most cases, is caused by cardiovascular disease. This state-of-the-art review aims to address the complex association between SMI and cardiovascular risk, explore disparities in cardiovascular care pathways, describe how to adequately predict cardiovascular outcomes, and propose targeted interventions to improve cardiovascular health in patients with SMI. These patients have an adverse cardiovascular risk factor profile due to an interplay between biological factors such as chronic inflammation, patient factors such as excessive smoking, and healthcare system factors such as stigma and discrimination. Several disparities in cardiovascular care pathways have been demonstrated in patients with SMI, resulting in a 47% lower likelihood of undergoing invasive coronary procedures and substantially lower rates of prescribed standard secondary prevention medications compared with the general population. Although early cardiovascular risk prediction is important, conventional risk prediction models do not accurately predict long-term cardiovascular outcomes as cardiovascular disease and mortality are only partly driven by traditional risk factors in this patient group. As such, SMI-specific risk prediction models and clinical tools such as the electrocardiogram and echocardiogram are necessary when assessing and managing cardiovascular risk associated with SMI. In conclusion, there is a necessity for differentiated cardiovascular care in patients with SMI. By addressing factors involved in the excess cardiovascular risk, reconsidering risk stratification approaches, and implementing multidisciplinary care models, clinicians can take steps towards improving cardiovascular health and long-term outcomes in patients with SMI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538149/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38538149</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae054>10.1093/eurheartj/ehae054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538149</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Christoffer Polcwiartek</dc:creator>
<dc:creator>Kevin O'Gallagher</dc:creator>
<dc:creator>Daniel J Friedman</dc:creator>
<dc:creator>Christoph U Correll</dc:creator>
<dc:creator>Marco Solmi</dc:creator>
<dc:creator>Svend Eggert Jensen</dc:creator>
<dc:creator>René Ernst Nielsen</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Severe mental illness: cardiovascular risk assessment and management</dc:title>
<dc:identifier>pmid:38538149</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae054</dc:identifier>
</item>
<item>
<title>Sacubitril/Valsartan-Related Hypotension in Patients with Heart Failure and Preserved or Mildly Reduced Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38537919/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In PARAGON-HF, a higher LVEF was associated with an increased risk of hypotension in patients treated with sacubitril/valsartan compared with valsartan. Since these subjects are also less likely to derive clinical benefit from sacubitril/valsartan, our data reinforce that the benefit/risk ratio favors the use of sacubitril/valsartan in patients with LVEF below normal, but not at higher LVEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 13:S0735-1097(24)00478-9. doi: 10.1016/j.jacc.2024.02.035. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Hypotension is a potential adverse effect of sacubitril/valsartan, but there are limited data regarding the predictors and implications of treatment-related hypotension in HFmrEF and HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We investigated predictors of treatment-associated hypotension, clinical outcomes after hypotension, and the relationship between LVEF and incidence of hypotension in the PARAGON-HF trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: PARAGON-HF randomized patients with chronic HF (≥45%) to sacubitril/valsartan or valsartan. Following randomization, hypotension was defined as investigator-reported hypotension with a SBP &lt;100 mmHg. Predictors of hypotension were assessed using multivariable Cox models. Associations between hypotension and clinical outcomes were evaluated in time-updated Cox models. The relationship between treatment, LVEF, and incident rates of hypotension and clinical outcomes was estimated using Poisson regression models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 4,796 patients in PARAGON-HF, 637 (13%) experienced hypotension, more frequently in the sacubitril/valsartan arm (p&lt;0.001). Following documented hypotension, patients had higher risk of CV death and total HF hospitalizations (adjusted RR 1.63; CI 1.27-2.09; p&lt;0.001) and all-cause death (adjusted HR 1.62; CI 1.28-2.05; p&lt;0.001). LVEF modified the association between sacubitril/valsartan and risk of hypotension (P<sub>interaction</sub>=0.019) such that patients with LVEF≥60% experienced substantially higher treatment-related risks of hypotension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In PARAGON-HF, a higher LVEF was associated with an increased risk of hypotension in patients treated with sacubitril/valsartan compared with valsartan. Since these subjects are also less likely to derive clinical benefit from sacubitril/valsartan, our data reinforce that the benefit/risk ratio favors the use of sacubitril/valsartan in patients with LVEF below normal, but not at higher LVEF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38537919/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38537919</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.035>10.1016/j.jacc.2024.02.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38537919</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Alberto Foà</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Maria A Pabon</dc:creator>
<dc:creator>Henri Lu</dc:creator>
<dc:creator>Marc A Pfeffer</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Orly Vardeny</dc:creator>
<dc:creator>Jean L Rouleau</dc:creator>
<dc:creator>Martin Lefkowitz</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>John Jv McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sacubitril/Valsartan-Related Hypotension in Patients with Heart Failure and Preserved or Mildly Reduced Ejection Fraction</dc:title>
<dc:identifier>pmid:38537919</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.035</dc:identifier>
</item>
<item>
<title>Dapagliflozin and days of full health lost through death, hospitalization, and impaired well-being in DAPA-HF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38537918/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240328141103&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Dapagliflozin reduced the total days of potential full health lost due to death, hospitalizations, and impaired well-being, and this benefit increased over time during the first year.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 25:S0735-1097(24)06671-3. doi: 10.1016/j.jacc.2024.03.385. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Conventional time-to-first-event analyses cannot incorporate recurrent hospitalizations and patient well-being in a single outcome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To overcome this limitation, we tested an integrated measure that includes days lost from death and hospitalization, and additional days of full health lost through diminished well-being.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The effect of dapagliflozin on this integrated measure was assessed in the DAPA-HF trial, which examined the efficacy of dapagliflozin, compared with placebo, in patients with NYHA class II-IV HF and a LVEF ≤40%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over 360 days, patients in the dapagliflozin group (n=2,127) lost 10.6±1.0 [mean±SE] (2.9%) of potential follow-up days through cardiovascular death and HF hospitalization, compared with 14.4±1.0 days (4.0%) in the placebo group (n=2,108), and this component of all measures of days lost accounted for the greatest between-treatment difference [-3.8 (95%CI -6.6 to -1.0) days]. Patients receiving dapagliflozin also had fewer days lost to death and hospitalization from all causes, versus placebo [15.5±1.1 days (4.3%) vs. 20.3±1.1 days (5.6%)]. When additional days of full health lost (i.e., adjusted for KCCQ-OSS) were added, total days lost were 110.6±1.6 (30.7%) with dapagliflozin vs.116.9±1.6 days (32.5%) with placebo]. The difference in all measures between the two groups increased over time; i.e., days lost by death and hospitalization -0.9 days (-0.7%) at 120 days, -2.3 days (-1.0%) at 240 days, and -4.8 days (-1.3%) at 360 days.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Dapagliflozin reduced the total days of potential full health lost due to death, hospitalizations, and impaired well-being, and this benefit increased over time during the first year.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38537918/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240328141103&v=2.18.0.post9+e462414">38537918</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.385>10.1016/j.jacc.2024.03.385</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38537918</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Toru Kondo</dc:creator>
<dc:creator>Ulrik M Mogensen</dc:creator>
<dc:creator>Atefeh Talebi</dc:creator>
<dc:creator>Samvel B Gasparyan</dc:creator>
<dc:creator>Ross T Campbell</dc:creator>
<dc:creator>Kieran F Docherty</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:creator>Silvio E Inzucchi</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>Felipe A Martinez</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:creator>Olof Bengtsson</dc:creator>
<dc:creator>Mikaela Sjöstrand</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>John Jv McMurray</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Dapagliflozin and days of full health lost through death, hospitalization, and impaired well-being in DAPA-HF</dc:title>
<dc:identifier>pmid:38537918</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.385</dc:identifier>
</item>





























</channel>
</rss>